2 Beaten-Down Stocks to Avoid Right Now
The biotech industry is notoriously volatile. Drugmakers often face significant challenges that send their stocks plummeting. Sometimes that creates an attractive entry point, provided we can reasonably expect the company in question to bounce back. But at other times it's not worth investing in a biotech stock that has lost significant market value, as the risks are still too high.
That's the case with Intellia Therapeutics (NASDAQ: NTLA) and Sarepta Therapeutics (NASDAQ: SRPT). These two biotechs have faced headwinds this year that have sent their share prices sinking, but investors should think twice before buying the dip.
Image source: Getty Images.
Source Fool.com
Sarepta Therapeutics Aktie
15,12 €
-7,10 %
Die Community ist unsicher über Sarepta Therapeutics: Zu wenige Buy- und Sell-Einschätzungen vorhanden.
Mit einem Kursziel von 135 € für Sarepta Therapeutics zeigt sich ein beachtliches Wachstumspotenzial gegenüber dem aktuellen Kurs von 15.12 €.
